Get introduced to the
most exciting companies in
our portfolio.

Tasca

tascatx.com

By harnessing the power of mass spectrometry-based proteomics to identify cancer-causing proteins that undergo a specific post-translational modification called auto-palmitoylation, Tasca is uniquely positioned to utilize previously unknown binding pockets to develop novel therapies for difficult-to-treat cancers. Tasca’s lead program, CP-383, is being developed to treat patients with tumors harboring a specific genetic profile and is expected to enter clinical trials in 2025.